

Application number
2506782

Type(s)
Standard Characters

Category
Trademark

CIPO Status
FORMALIZED

TM5 status
LIVE/APPLICATION/ Awaiting Examination



The trademark application has been accepted by the Office (has met the minimum filing requirements) and has not yet been assigned to an examiner.

Filed
2026-10-09

Applicant
ABIVAX, Société de droit français
7-11 Blvd. Haussmann
75009 PARIS,
FRANCE

Agent
ROBIC AGENCE PI S.E.C./
ROBIC IP AGENCY LP
630, boul. René-Lévesque
Ouest
20e étage
Montréal
QUÉBEC H3B1S6

Documents
[View documents](#)

Action History

Action	Action date	Due date	Comments
Filed	2026-10-09		
Created	2026-10-09		

Index headings

BYLTIMRIZ

Goods (Nice class & Statement)

5 (1) Pharmaceutical preparations for the treatment of inflammatory diseases, immune-mediated and autoimmune diseases, disorders and conditions affecting the gastrointestinal tract, namely, inflammation associated with colon carcinoma, pouchitis, Inflammatory Bowel Disease, including Crohn's disease and Ulcerative Colitis, checkpoint inhibitor colitis and eosinophilic esophagitis; Chemical preparations for medical purposes for the treatment of inflammatory diseases, immune-mediated and autoimmune diseases, disorders and conditions affecting the gastrointestinal tract, namely, inflammation associated with colon carcinoma, pouchitis, Inflammatory Bowel Disease, including Crohn's disease and Ulcerative Colitis, checkpoint inhibitor colitis and eosinophilic esophagitis; Chemical preparations for pharmaceutical purposes for the treatment of inflammatory diseases, immune-mediated and autoimmune diseases, disorders and conditions affecting the gastrointestinal tract, namely, inflammation associated with colon carcinoma, pouchitis, Inflammatory Bowel Disease, including Crohn's disease and Ulcerative Colitis, checkpoint inhibitor colitis and eosinophilic esophagitis.

Claims

Priority Filing Date: October 08, 2026, Country or Office: FRANCE, Application No. 5306669 in association with the same kind of goods

Formalized	2026-10-09		
------------	------------	--	--